title: Risk of residual disease and invasive carcinoma in women treated for adenocarcinoma in situ of the cervix.
abstract: OBJECTIVE
  Cervical adenocarcinoma in situ (AIS) is increasing in incidence among reproductive-age women. Cervical conization is an alternative to hysterectomy that allows future fertility, however reports regarding the risk of residual AIS and underlying adenocarcinoma are conflicting. The purpose of this study was to determine the outcomes of a large cohort of women treated for AIS.
  
  
  METHODS
  The medical records of 180 women with cervical AIS evaluated at the University of Texas MD Anderson Cancer Center and its outlying clinics between 1983 and 2011 were reviewed for demographic information, treatment history, pathologic findings and outcomes.
  
  
  RESULTS
  The mean age at diagnosis was 33.8years (range 17.6-76.1years). 172 of the 180 women had at least one cone biopsy performed, with 110 (64.0%) undergoing a cold knife cone (CKC), and 62 (36.0%) undergoing a loop electrosurgical excision procedure (LEEP) as their initial method of treatment. Positive margins were noted in 35.0% of patients undergoing CKC compared with 55.6% undergoing LEEP (p=0.017). 71 patients ultimately underwent hysterectomy with residual disease noted in 10 patients (14.1%), 8 patients (11.3%) with residual AIS and 2 patients (2.8%) with invasive carcinoma. Of the 101 patients who did not undergo hysterectomy, 2 patients (2.0%) developed recurrent AIS at a median of 27.5months (range 18-37months) from the last cone, and none developed invasive carcinoma.
  
  
  CONCLUSIONS
  Patients undergoing conservative management for AIS with cervical conization alone should be monitored closely and counseled regarding the potential risks of residual and recurrent disease, even when negative cone margins are obtained.
authors.affiliation: Department of Gynecologic Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
authors.forename: Anthony B
authors.initials: AB
authors.lastname: Costales
authors.forename: Andrea M
authors.initials: AM
authors.lastname: Milbourne
authors.forename: Helen E
authors.initials: HE
authors.lastname: Rhodes
authors.forename: Mark F
authors.initials: MF
authors.lastname: Munsell
authors.forename: John J
authors.initials: JJ
authors.lastname: Wallbillich
authors.forename: Jubilee
authors.initials: J
authors.lastname: Brown
authors.forename: Michael
authors.initials: M
authors.lastname: Frumovitz
authors.forename: Lois M
authors.initials: LM
authors.lastname: Ramondetta
authors.forename: Kathleen M
authors.initials: KM
authors.lastname: Schmeler
mesh_terms: D000230:Adenocarcinoma / Q000473:pathology* / Q000601:surgery*; D000293:Adolescent; D000328:Adult; D000368:Aged; D002278:Carcinoma in Situ / Q000473:pathology* / Q000601:surgery*; D015331:Cohort Studies; D019092:Conization / Q000379:methods; D003452:Cryosurgery / Q000379:methods; D004598:Electrosurgery / Q000379:methods; D005260:Female; D006801:Humans; D007044:Hysterectomy; D008875:Middle Aged; D009361:Neoplasm Invasiveness; D018365:Neoplasm, Residual; D012307:Risk Factors; D016896:Treatment Outcome; D002583:Uterine Cervical Neoplasms / Q000473:pathology* / Q000601:surgery*; D055815:Young Adult
references.citation: Gynecol Oncol. 1996 Jun;61(3):304-8
references.pmid: 8641606
references.citation: Gynecol Oncol. 2000 May;77(2):334-5
references.pmid: 10785491
references.citation: Gynecol Oncol. 2005 Nov;99(2):489-92
references.pmid: 16054200
references.citation: BMJ. 2008 Sep 18;337:a1284
references.pmid: 18801868
references.citation: Obstet Gynecol. 2001 Nov;98(5 Pt 1):726-31
references.pmid: 11704160
references.citation: Obstet Gynecol. 1997 Jul;90(1):1-6
references.pmid: 9207802
references.citation: Gynecol Oncol. 2012 Mar;124(3):490-5
references.pmid: 22188786
references.citation: Gynecol Oncol. 2000 Nov;79(2):207-10
references.pmid: 11063645
references.citation: Cancer Epidemiol Biomarkers Prev. 2001 Mar;10(3):171-7
references.pmid: 11303584
references.citation: Gynecol Oncol. 2004 May;93(2):465-8
references.pmid: 15099963
references.citation: Lancet. 2006 Feb 11;367(9509):489-98
references.pmid: 16473126
references.citation: Obstet Gynecol. 1996 Jul;88(1):82-6
references.pmid: 8684768
references.citation: Gynecol Oncol. 1995 Nov;59(2):179-82
references.pmid: 7590468
references.citation: Gynecol Oncol Case Rep. 2012 May 09;2(3):97-9
references.pmid: 24371632
references.citation: Gynecol Oncol. 2007 Nov;107(2):316-9
references.pmid: 17689593
references.citation: Int J Gynaecol Obstet. 2012 Dec;119(3):266-9
references.pmid: 22939281
references.citation: Am J Obstet Gynecol. 2007 Oct;197(4):340-5
references.pmid: 17904956
references.citation: Am J Obstet Gynecol. 2009 Feb;200(2):182.e1-5
references.pmid: 19019325
references.citation: BMJ. 2008 Sep 18;337:a1343
references.pmid: 18801869
references.citation: Gynecol Oncol. 2000 Oct;79(1):6-10
references.pmid: 11006022
references.citation: Am J Obstet Gynecol. 1952 Apr;63(4):800-8
references.pmid: 14914786
references.citation: Gynecol Oncol. 2002 Sep;86(3):361-4
references.pmid: 12217762
references.citation: Gynecol Oncol. 2007 Jul;106(1):170-6
references.pmid: 17481701
references.citation: Gynecol Oncol. 1996 Jun;61(3):301-3
references.pmid: 8641605
references.citation: Gynecol Oncol. 1995 May;57(2):158-64
references.pmid: 7729727
references.citation: J Low Genit Tract Dis. 2004 Apr;8(2):125-31
references.pmid: 15874850
references.citation: BJOG. 2001 Nov;108(11):1184-9
references.pmid: 11762660
references.citation: Gynecol Oncol. 2000 Oct;79(1):4-5
references.pmid: 11006021
references.citation: Gynecol Oncol. 2002 Sep;86(3):365-9
references.pmid: 12217763
references.citation: Obstet Gynecol. 1988 Jun;71(6 Pt 1):842-4
references.pmid: 3285263